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Data were obtained via self-administered questionnaire and tele-
phone using trained interviewers. QOL domains used were those
identiﬁed by the OAB-q instrument developed by Coyne et al.
All proﬁle attributes had two levels: high/present and low/not
present. RESULTS: The linear ﬁxed-effects model resulted in the
following part-worth coefﬁcients for the ﬁve attributes of inter-
est: insurance coverage, 34.17; sleep, 23.55; concern, 19.59;
social, 19.28; coping, 15.61. Also reported is an analysis of
demographic variables with respect to symptom severity and
QOL. CONCLUSIONS: When deciding to treat OAB symptoms
with prescription medications, patients place the most impor-
tance on prescription drug insurance coverage. QOL domains
follow insurance in this order: sleep disturbances, symptom
concern, social disturbances, and coping.
URINARY/KIDNEY DISEASES/DISORDERS
URINARY/KIDNEY DISEASES/DISORDERS—Health
Policy Studies
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PATIENT PERSISTENCY WITH MEDICATIONS FOR
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Chui MA1,Williamson T2,Arciniega J3,Thompson C2, Benecke H3
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OBJECTIVES: To assess patient persistency in maintaining treat-
ment for Overactive Bladder (OAB). METHODS: Patients initi-
ating therapy on oxybutynin or tolterodine, immediate or
extended release, were tracked for 12-months, using a retail
pharmacy database. Five persistency classiﬁcation categories
were created to evaluate persistency as follows: on therapy, dis-
continued/no switch, discontinued/switched to one of the other
previously listed medications, reinitiated initial therapy, and off
therapy. Measurements included tracking the percent of patients
within each persistency classiﬁcation category, total therapy
days, and prescriptions dispensed for all medications. RESULTS:
The percentage of patients that discontinued their current
therapy and did not switch to another OAB therapy was 46.9%
at month three. By month four, more than half of all patients
were off therapy (55.4%). The percentage of patients off therapy
increased each month and reached 81.6% by the end of twelve
months. The percentage of patients that were switched to
another OAB medication did not exceed 3% in any month, nor
did the percentage of patients who reinitiated their initial therapy
surpass 3% in any month. The mean length of therapy was
approximately 86 days, with an average days supply of 30.
Approximately half of all patients were dispensed only one 
medication during the 12-month period. CONCLUSIONS:
Patient persistency with any currently marketed medications for
OAB remains poor, with less than 20% of study patients remain-
ing on therapy after 1 year.
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OBJECTIVES: The objectives of PURE are to understand the
direct cost of urinary incontinence (UI); describe the impact of
UI on health-related quality of life (HRQOL); and describe the
treatment patterns for women with UI in Europe in an outpa-
tient setting. METHODS: PURE is an ongoing, prospective,
observational study. More than 9000 patients will be recruited
in 13 European countries. The participating investigators are
primary care physicians and specialists (urologists, gynaecolo-
gists, geriatricians). The data will be prospectively collected at
baseline and at 2 points over a 6-month period. Assessments
include health care resource utilisation and treatments to derive
direct medical costs of UI care and describe the treatment pat-
terns, as well as symptoms and severity of UI and impact of UI
on patients’ lives. Baseline evaluation will additionally include
demographics, medical history, the assessment of HRQOL and
a retrospective data collection on health care resource utilisation
in the previous 12 months. RESULTS: By considering all the 10
priority research areas on the economics of UI identiﬁed by the
2nd international consultation on incontinence, PURE provides
a unique opportunity to assess the direct medical costs for UI
care in women across Europe. This will give insights to the eco-
nomic burden from the perspective of the national health care
systems, as well as from the patient, and will allow comparisons
of treatment patterns between countries in the light of different
health care systems and access to care. To our knowledge this is
the ﬁrst study undertaken in an outpatient setting to investigate
the economic and human impact of UI in Europe. CONCLU-
SIONS: PURE will address relevant clinical, economic and policy
research questions and will provide large-scale, comparative,
real-world information on the treatment and burden of UI across
Europe; data currently missing from the European literature but
needed to guide effective health policy.
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OBJECTIVES: Acute renal failure (ARF) is a prevalent and 
often preventable adverse drug event. Automated methods for
ARF identiﬁcation facilitate quality improvement and outcome
research, but traditional reliance on ICD9 codes has been shown
to underestimate the incidence. This study aimed to develop and
validate automated algorithms for the identiﬁcation of hospital-
acquired ARF. METHODS: A panel (nephrologist, internist,
clinical pharmacy specialist, pharmacoepidemiologist, database
analyst) deﬁned 3 algorithms based on existing literature and
available automated data: 1) 50% increase of serum creatinine
(SCr) within 3 days; 2) 50% SCr decrease between peak and 
discharge; and 3) ICD9 584.•• and charge code for dialysis. 
Each algorithm was linked (temporally and proximately) to 
drug exposure (aminoglycosides, amphotericin, cyclosporine,
tacrolimus, NSAIDs, or radiocontrast). Discharges with hospital
days <2 or ESRD (dialysis in ﬁrst 3 days of admission) were
excluded. Algorithms were applied to the laboratory and admin-
istrative databases of a large teaching hospital including dis-
charges between July 1, 2001 and June 30, 2002 (n = 20,639 or
10,536 with nephrotoxic drugs). Senior nephrology fellows to
verify the algorithms reviewed a random sample of positive
screened discharges. A random 20% of these were re-reviewed
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to assess inter-rater reliability. RESULTS: The 3 algorithms
found 725 unique discharges (incidence 6.9%) with ARF. Algo-
rithm 1 identiﬁed 585 cases, 2 and 3 identiﬁed 264 and 72. Of
these, a random sample of 99 charts (stratiﬁed by algorithm) was
reviewed. Reviewers anonymously conﬁrmed ARF in 87 (88%)
of 99 charts. The ﬂagged association with the speciﬁed nephro-
toxin was conﬁrmed in 48 (55%) cases. Positive predictive values
for each algorithm were comparable, 88%, 93%, and 87%
respectively, while estimated sensitivity (78%, 47%, 15%) and
speciﬁcity (25%, 75%, 83%) varied. CONCLUSIONS: The
algorithms offer an excellent tool for outcomes research. While
each is valid in correctly identifying ARF, differences exist in sen-
sitivity and speciﬁcity. Underlying study questions (e.g., desired
ARF severity) should determine which algorithm is used.
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A COST MINIMIZATION ANALYSIS OF FOMEPIZOLE VERSUS
ETHANOL WITH OR WITHOUT HEMODIALYSIS IN THE
ACUTE MANAGEMENT OF METHANOL OR ETHYLENE-
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OBJECTIVES: To evaluate from the public payer point of view
savings in the acute management of methanol or ethylene glycol
poisoning when replacing ethanol by fomepizole as ﬁrst line anti-
dote therapy. METHODS: A decision tree model based on a
expert consensus process was built, using DATA TM Tree Age
4.0, to predict the average additional costs per patient due to the
treatment of side effects of each antidote in 8 situations
(branches). The side effects were related to the following issues:
depression of the central nervous system, pancreatitis, and
hemodialysis complications. For each of the ﬁve countries
(Belgium, France, Italy, Ireland, Norway) one senior expert in
toxicology and intensive care provided: 1) An estimation of the
probability of occurrence of each side effect, and 2) A value (real
price) of each relevant treatment of each side effect. The costs
were given as per-S2 2003 value. As the time frame of the study
was the discharge of hospital, no discount rate was calculated.
RESULTS: In each of the ﬁve countries, the cost of side effect
management was cheaper in the “fomepizole” situation than in
the “ethanol” situation. For methanol poisoning, the savings in
the fomepizole group ranged from 724€ to 1667€, 22.3% to
88.7% in proportion. For ethylene-glycol poisoning the saving
in the fomepizole group ranged from 251€ to 2847€, 26.3% to
76.9% in proportion. CONCLUSION: Fomepizole, when used
as a ﬁrst line antidote therapy represents a source of potential
savings in the management of side effects: Up to 1667€ for
methanol poisoning and up to 2847 € for ethylene glycol 
poisoning.
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O’Brien J1, Pitoniak-Morse C1, Jacobs L2
1Caro Research Institute, Concord, MA, USA; 2University of
Connecticut School of Medicine, Farmington, CT, USA
OBJECTIVE: Each year in the U.S., particularly around holidays
like July 4th, injuries occur from the use of ﬁreworks. Most
injuries can be treated in Emergency Departments, but some are
serious enough to require hospitalization. This study examines
admissions resulting from ﬁreworks-related injuries and esti-
mates the resulting hospital cost. METHODS: Cases were iden-
tiﬁed using ICD-9 diagnosis and E-codes. Hospital costs were
developed based on discharge data from 59 hospitals in seven
states from 2000. Cost estimates include accommodation and
ancillary services, reported in 2003 US$. Charges were adjusted
using a 0.61 cost-to-charge ratio and the U.S. Consumer Price
Index’s annual medical care component. RESULTS: Of 98 cases
identiﬁed, 90% were male. Admissions occurring in July (35%),
June (15%) and January (16%) accounted for two-thirds of 
hospitalizations. Mean age was 25 years (median: 18, range:
5–75), 40% were under 15 years. Most (78%) were admitted
via the Emergency Department and 40% stayed in ICU. Princi-
pal diagnoses revealed that 41% were admitted primarily for
fracture or open wound of an extremity; second or third degree
burns (25%) or eye injuries (17%). Roughly, one third (34%)
required amputation of a ﬁnger or thumb. No fatalities were
reported. Mean length of stay was 4 days (median: 2, range:
1–41). Mean cost per stay was $15,590 (median: $7150, range:
$923–$235,213). Cumulative cost for all cases was approxi-
mately $1.4 million. At discharge 94% went home (4% with
home care) and the remaining 6% were transferred to sub-acute
facilities. CONCLUSIONS: Most of the ﬁreworks-related
injuries requiring hospital level of care occurred in children and
teenagers. Some injuries can be potentially life altering because
of amputation or loss of an eye. These results bring attention to
the need for increased education, particularly prior to holidays,
of children and their parents about the dangers and consequences
of using ﬁreworks.
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OBJECTIVES: To identify youths (infants -19 years) admitted
for a handgun-related injury and associated resource use and
costs. METHODS: Hospital data for discharges in 2000 from 
7 states were examined using ICD-9 diagnosis and E-codes
(E922.0, E955.0, E965.0) to identify type and circumstance (i.e.,
assault, accident, self-inﬂicted) of injury along with demograph-
ics, costs, length of stay (LOS), case fatality rate (CFR) and dis-
position. Charges were adjusted using a 0.61 cost-to-charge ratio
and the annual medical care component of the U.S. Consumer
Price Index. Cost estimates include all accommodations and
ancillary services, reported in 2003 US$. RESULTS: Of the 2498
handgun-related admissions identiﬁed, 22% involved a child 
or teen (n = 541; males = 86%). Assaults were noted in 67% 
of cases, followed by accidents (27%) and self-inﬂicted (6%)
injuries. Most (86%) were admitted via the Emergency Depart-
ment. Mean age was 16 years, but most (53%) were 18–19 years;
6% were under 12 years. On average, those with accident-related
injuries were younger (mean = 14 years). The CFR was 4% 
for assault-related cases, 8% for accidental injuries. More 
than half (57%) of those with self-inﬂicted injuries died as inpa-
tients. Head injuries comprised 70% of self-inﬂicted injuries.
Extremity injuries were coded most often in accidental shootings
(54%); trunk injuries (45%) in assaults. Mean LOS for handgun
injuries was 5 days (median: 3, range: 1–53). Mean cost per stay
was $17,000 (median: $10,500, range: $560–$1.2 million).
Cumulative cost for all cases was $12.8 million. Among sur-
vivors, 89% went home (8% with home care), 5% required sub-
acute inpatient care, 2% left AMA and 4% to an institution (e.g.,
prison). CONCLUSIONS: Most hospitalizations were assault-
related. Intentional injuries were seen least often, but were the
